Introduction
Methods
Results
Patient characteristics
Variable | Value |
---|---|
Recipient data | |
Time from HTX until COVID-19 (days) | 2858.3 (± 2516.4) |
Time from COVID-19 until last follow-up (days) | 35.6 (± 19.0) |
Age (years) | 58.6 (± 12.3) |
Male sex | 17 (81.0) |
Body mass index (kg/m2) | 25.1 (± 3.6) |
Cardiac allograft vasculopathy | 4 (19.0) |
Arterial hypertension | 15 (71.4) |
Dyslipidemia | 15 (71.4) |
Diabetes mellitus | 7 (33.3) |
Dialysis | 6 (28.6) |
COPD/Asthma | 4 (19.0) |
Principal diagnosis for HTX | |
Ischemic cardiomyopathy | 5 (23.8) |
Dilated cardiomyopathy | 13 (61.9) |
Hypertrophic cardiomyopathy | 1 (4.8) |
Restrictive cardiomyopathy | 0 |
Arrhythmogenic cardiomyopathy | 1 (4.8) |
Congenital heart disease | 1 (4.8) |
Immunosuppressive therapy | |
Cyclosporine A | 5 (23.8) |
Tacrolimus | 10 (47.6) |
Azathioprine | 0 |
Mycophenolate mofetil | 18 (85.7) |
Everolimus | 8 (38.1) |
Sirolimus | 1 (4.8) |
Steroids | 15 (71.4) |
Concomitant medication | |
Aspirin or clopidogrel | 14 (66.7) |
Beta blocker | 6 (28.6) |
Calcium channel blocker | 9 (42.9) |
Ivabradine | 4 (19.0) |
ACE-I/ARB | 8 (38.1) |
Statin | 18 (85.7) |
Clinical presentation and treatment
Variable | Value |
---|---|
Symptoms | |
Cough | 16 (76.2) |
Rhinitis | 14 (66.7) |
Fever | 14 (66.7) |
Dyspnea | 18 (85.7) |
Myalgia/fatigue | 16 (76.2) |
Diarrhea | 6 (28.6) |
Pain | 5 (23.8) |
Anosmia or loss of taste | 1 (4.8) |
Findings | |
Reduced LVEF | 0 (0.0) |
Reduced right ventricular function | 6 (28.6) |
Increased systolic PAP | 6 (28.6) |
Newly diagnosed moderate to severe or severe tricuspid regurgitation | 4 (19.0) |
New-onset arrhythmias | 4 (19.0) |
New-onset atrial fibrillation | 2 (9.5) |
New-onset ventricular tachycardia | 2 (9.5) |
New thromboembolic events | 4 (19.0) |
New deep vein thrombosis | 2 (9.5) |
New pulmonary embolism | 2 (9.5) |
Abnormal chest CT | 16 (76.2) |
Treatment | |
Piperacillin/tazobactam | 12 (57.1) |
Meropenem | 9 (42.9) |
Azithromycin | 4 (19.0) |
Caspofungin | 4 (19.0) |
Hydroxychloroquine | 3 (14.3) |
Pausing of mycophenolate mofetil | 11 (52.4) |
Switch from sirolimus to tacrolimus | 1 (4.8) |
Oxygen supply | 18 (85.7) |
Non-invasive ventilation | 8 (38.1) |
Invasive mechanical ventilation | 8 (38.1) |
New-onset dialysis | 5 (23.8) |
ECLS | 3 (14.3) |
Laboratory findings
Variable | Value |
---|---|
Cardiac markers | |
hs-cTnT (pg/ml) | 137.5 (± 113.3) |
NT-proBNP (ng/l) | 9426.2 (± 12,835.1) |
Blood count | |
White-cell count (/nl) | 12.0 (± 6.1) |
Neutrophil count (%) | 83.4 (± 3.8) |
Lymphocyte count (%) | 9.2 (± 5.4) |
Red-cell count (/pl) | 3.9 (± 0.7) |
Hemoglobin (g/dl) | 1.4 (± 2.2) |
Hematocrit (l/l) | 0.34 (± 0.07) |
Platelet count (/nl) | 288.0 (± 163.3) |
Renal markers | |
Creatinine (mg/dl) | 4.3 (± 3.1) |
Blood urea nitrogen (mg/dl) | 120.7 (± 64.3) |
Glomerular filtration rate (ml/min/1.73 m2) | 26.7 (± 21.0) |
Markers of infection | |
C-reactive protein (mg/l) | 132.7 (± 109.0) |
Procalcitonin (ng/ml) | 5.9 (± 8.2) |
Lactate dehydrogenase (U/l) | 635.6 (± 317.1) |
Ferritin (µg/l) | 2619.4 (± 2451.4) |
D-dimer (mg/l) | 4.4 (± 3.2) |
Comparison between patients with severe and non-severe disease
Variable | Non-severe course (n = 13) | Non-severe course (n = 8) | p value |
---|---|---|---|
Invasive mechanical ventilation | 0 | 8 (100.0) | < 0.001 |
Age > 60 years | 4 (30.8) | 7 (87.5) | 0.028 |
Reduced right ventricular function | 1 (7.7) | 5 (62.5) | 0.014 |
New-onset arrhythmiasa | 0 | 4 (50.0) | 0.012 |
New thromboembolic eventsb | 0 | 4 (50.0) | 0.012 |
New-onset dialysis | 2 (15.4%) | 3 (37.5) | 0.325 |
Mortality | 0 | 7 (87.5) | < 0.001 |
White-cell count (/nl) | 10.6 (± 4.6) | 14.4 (± 7.5) | 0.181 |
Lymphocyte count (%) | 11.4 (± 5.3) | 5.5 (± 3.5) | 0.013 |
Platelet count (/nl) | 222.0 (± 104.8) | 395.1 (± 183.4) | 0.017 |
C-reactive protein (mg/l) | 102.5 (± 108.1) | 181.8 (± 91.1) | 0.116 |
Procalcitonin (ng/ml) | 1.9 (± 2.4) | 12.5 (± 9.8) | 0.002 |
Lactate dehydrogenase (U/l) | 421.8 (± 109.7) | 983.0 (± 222.5) | < 0.001 |
Ferritin (µg/l) | 2042.4 (± 2551.7) | 4119.6 (± 616.0) | 0.110 |
D-dimer (mg/l) | 3.0 (± 2.0) | 6.6 (± 3.5) | 0.011 |
hs-cTnT (pg/ml) | 93.9 (± 100.6) | 234.8 (± 88.2) | 0.017 |
NT-proBNP (ng/l) | 2203.9 (± 1857.2) | 21,162.5 (± 14,294.5) | < 0.001 |